ProMIS Neurosciences Inc. (PMN) Form 10-Q — Aug 13, 2026
ProMIS Neurosciences filed its Q2 2026 Form 10-Q reporting a net loss of $11.7 million for the quarter and $20.0 million for the first half of 2026, with no product revenue and an accumulated deficit of $150.4 million. First-half R&D spending rose 16% year over year to $16.5 million, driven largely by the PMN310 Phase 1b program. Liquidity was bolstered by the January 2026 PIPE, which generated $70.1 million in net proceeds ($75.5 million gross).
Key figures
- Revenue
- 0
- Cash runway
- through 2027
- Atm capacity
- $50.0 million (upsized March 2026)
- Ga expense 6m
- 4418497
- Rd expense 6m
- 16492799
- Interim aria e
- 0
- Pmn310 spend 6m
- $14.0 million
- Working capital
- approximately $49.5 million
- Precise ad sites
- 21
- Interim total aria
- 4.4% (all mild/asymptomatic ARIA-H)
- Accumulated deficit
- $150.4 million
- Options outstanding
- 1033489
- Reverse split ratio
- 1-for-25 (November 2025)
- Fully diluted shares
- 19341355
- Warrants outstanding
- 9340131
- Ga expense growth pct
- 29
- Rd expense growth pct
- 16
- Interim apoe4 carrier pct
- 61
- Interim patients evaluated
- 136
- Jan 2026 pipe net proceeds
- $70.1 million
- Jan 2026 pipe gross proceeds
- $75.5 million
- Precise ad subjects enrolled
- 144
- Shares outstanding aug 13 2026
- 8967693
- Ptau217 decline pct of patients
- 68.5
- Mtbr tau243 decline pct of patients
- 62.5
Price after filing
1 day: +0.5%7 days: +0.8%30 days: -8.3%
Close on the filing date to close N calendar days later (from $14.79). Historical, not a forecast.
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.